Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) — Form 8-K: Current report
AI-generated summary
Revolution Medicines, Inc. filed a current report on October 13, 2026. The company reported that on October 8, 2026, following FDA approval of RASONQUE for metastatic pancreatic adenocarcinoma, a lender advanced a $250.0 million Tranche A Loan under an existing agreement. The company paid a $5.0 million draw fee and opted not to take an additional Tranche 3 purchase price of $250.0 million.
Key facts
- Item 2.03 · New debt or another financial obligation
- Item 8.01 · Other events
More RVMD filings
- SC 13G
Filed Oct 30, 2026
- 4
Filed Oct 28, 2026
- 4
Filed Oct 1, 2026
- 4
Filed Sep 29, 2026
- 144
Filed Sep 29, 2026
- 4
Filed Sep 28, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.